Physician profile
Atul Sachdev
NPI 1700884509
$9,551.27
in general payments reported to CMS, 2019-2025
32 companies · $419 in 2025
The $419 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $337 · 2021: $5,934 · 2022: $789 · 2023: $797 · 2024: $1,010 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,225.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $5,078.73 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $890.83 | 2020-2025 | Farxiga, Airsupra |
| Abbvie INC. | $672.98 | 2021-2025 | Vraylar, Ubrelvy, Botox |
| Lilly USA, LLC | $461.70 | 2020-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $452.83 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $333.63 | 2019-2025 | Repatha, Otezla, Otezla |
| Esperion Therapeutics, INC. | $332.15 | 2020-2025 | Nexletol |
| Biohaven Pharmaceuticals, INC. | $170.96 | 2020-2021 | |
| Allergan, INC. | $152.43 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $141.89 | 2019-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $125.35 | 2020-2023 | Steglatro, Segluromet, Steglujan |
| Idorsia Pharmaceuticals US INC | $111.48 | 2022-2024 | Quviviq |
| Exact Sciences Corporation | $97.82 | 2024-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $68.00 | 2023-2024 | Rexulti |
| Verity Pharmaceuticals INC. | $61.48 | 2025 | Tlando |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $49.99 | 2022-2025 | |
| Shire North American Group INC | $44.75 | 2019 | |
| Axsome Therapeutics, INC. | $40.66 | 2024-2025 | Auvelity |
| Inspire Medical Systems, INC. | $37.02 | 2025 | Inspire |
| Biohaven Pharmaceutical Holding Company Ltd. | $34.40 | 2022 | |
| Antares Pharma, INC. | $20.65 | 2023 | Tlando, Xyosted, Nocdurna |
| Corium, LLC | $18.99 | 2022 | |
| Arbor Pharmaceuticals, INC. | $17.82 | 2019 | |
| Amarin Pharma, INC. | $17.73 | 2021 | |
| Tris Pharma INC | $17.28 | 2021 | |
| Azurity Pharmaceuticals, INC. | $17.20 | 2024 | |
| Paratek Pharmaceuticals, INC. | $17.02 | 2024 | Nuzyra |
| Adlon Therapeutics L.P. | $16.73 | 2021 | |
| Ascend Therapeutics US, LLC | $13.17 | 2020 | |
| Medtronic USA, INC. | $12.53 | 2019 | |
| Pfizer INC. | $11.59 | 2019 | |
| Genentech USA, INC. | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Atul Sachdev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.